Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 615, Issue 1-3, Pages 252-256Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2009.05.017
Keywords
Diphlorethohydroxycarmalol; alpha-glucosidase; alpha-amylase; Postprandial hyperglycemia; Diabetes
Categories
Funding
- Ministry for Food, Agriculture, Forestry and Fisheries of the Korean government [F20814808 H230000110]
Ask authors/readers for more resources
This study was designed to investigate whether diphlorethohydroxycarmalol (DPHC) may inhibit alpha-glucosidase and alpha-amylase activities, and alleviate postprandial hyperglycemia in streptozotocin-induced diabetic mice. DPHC isolated from Ishige okamurae, a brown algae, evidenced prominent inhibitory effect against alpha-glucosidase and alpha-amylase. The IC50 Values of DPHC against alpha-glucosidase and alpha-amylase were 0.16 and 0.53 mM, respectively, which evidenced the higher activities than that of acarbose. DPHC did not exert any cytotoxic effect in human umbilical vein endothelial cells (HUVECs) at various concentrations (from 0.49 to 3.91 mM). The increase of postprandial blood glucose levels were significantly suppressed. in the DPHC-administered group than those in the streptozotocin-induced diabetic or normal mice. Moreover, the area under curve (AUC) was significantly reduced via DPHC administration (2022 versus 2210 mmol-min/l) in the diabetic mice as well as it delays absorption of dietary carbohydrates. Therefore, these result indicated that DPHC might be a potent inhibitor for alpha-glucosidase and alpha-amylase. Crown Copyright 2009 Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available